Type 2 diabetes
Conditions
Interventions
Sponsors
Dokkyo Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients who continued diet and exercise therapy more than 12 weeks before day1. Exercise therapy is not essential if it is prohibited because of the complication 2)HbA1c levels of 6.9%<= to <10.4%, as defined by the National Institutes of Diabetes and Digestive and Kidney Diseases 3)Difference in HbA1c levels <0.5% at the start date and 4 weeks before the start of administration 4)Insufficient in an effect except DPP-4 inhibitor
Exclusion criteria
Exclusion criteria: 1)Type-1 diabetes, diabetes due to a pancreatic disorder, or secondary diabetes due to conditions such as Cushing's syndrome and acromegaly 2)Application of contraindications contained in the package insert 3)Heart failure (NYHA grade 3-4) 4)Patients prone to QT prolongation 5)Excessive alcohol consumption 6)Pregnant women, women suspected of being pregnant, or lactating women 7)History of myocardial infarction 8)The medication in the treatment of diabetes drugs not be used with insurance 9)Under administration of GLP-1 agonists
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in Glycosylated hemoglobin (HbA1c) levels over 24 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Echocardiography, Endothelial function, Biomarker | — |
Countries
Japan
Contacts
Public ContactShigeru Toyoda
Dokkyo Medical University Department of Cardiovascular Medicine
Outcome results
None listed